

Ref: MHL/Sec&Legal/2025-26/59

September 18, 2025

To,
BSE Limited
Scrip Code: 542650

National Stock Exchange of India Ltd.
Scrip Symbol: METROPOLIS

Dear Sir/Madam,

Sub: Press Release

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed herewith is the Press Release as mentioned below:

“Metropolis Healthcare Limited acquires Kolhapur’s Ambika Pathology Laboratory, Strengthening its Leadership in Western Maharashtra”

You are requested to take the above information on record.

Thanking you,
Yours faithfully,

For **Metropolis Healthcare Limited**

Kamlesh C Kulkarni
Head – Legal & Secretarial

Encl: A/a



PRESS RELEASE**Metropolis Healthcare Limited acquires Kolhapur's Ambika Pathology Laboratory, Strengthening its Leadership in Western Maharashtra.**

*~ Ambika Pathology to be developed into a **mini regional reference lab, offering 4,000+ advanced and specialty diagnostics** to patients in Kolhapur and neighbouring Tier-2 and Tier-3 towns ~*

India, Mumbai, 18th September 2025: Ameera Shah-led Metropolis Healthcare Limited (NSE: METROPOLIS | BSE: 542650), India's second-largest and most respected pathology laboratory chain, today announced the completion of its fourth acquisition in the last 10 months, with Dr. R.S. Patil's Ambika Pathology Laboratory ("Ambika Pathology") in Kolhapur joining the Metropolis network. Founded and operated by Dr. Rajendra Sadashiv Patil, the NABL-accredited facility is among the region's leading diagnostic providers and has been acquired through a Business Transfer Agreement. This marks a key milestone in Metropolis' "String of Pearls" strategy, which focuses on building strong regional clusters and expanding access to advanced diagnostics across India.

Established in 1995, Ambika Pathology Laboratory has built a strong reputation for quality, accuracy, and patient-centric care. The facility operates a central laboratory supported by 12 patient touchpoints and offers a comprehensive portfolio of tests. With nearly 75% of its revenue derived from B2C walk-in patients, Ambika has earned the trust of both patients and clinicians across Kolhapur and neighbouring towns. Its strong local connect makes it a strategic addition to Metropolis' Western Maharashtra cluster, where the company already operates 19 laboratories across Pune, Kolhapur, Sangli, Satara, Solapur, Nashik, and Ahmednagar, supported by more than 200 patient service centres and a growing franchise network.

Commenting on the acquisition, Ms. Ameera Shah, Promoter and Executive Chairperson, Metropolis Healthcare Limited said: "Maharashtra continues to be a key growth market for Metropolis, contributing nearly 40% of our total revenues. The acquisition of Ambika Pathology further strengthens our Western Maharashtra cluster and supports our ambition to make high-quality diagnostics accessible to more communities. At Metropolis, we are committed to building the diagnostics network of the future, rooted in science, powered by technology, and connected deeply with local healthcare ecosystems. Ambika's strong legacy and trusted regional presence make it a natural fit within our expanding B2C network, and we are delighted to welcome Dr. Rajendra Patil and his team into the Metropolis family."

Mr. Surendran Chemmenkotil, Managing Director, Metropolis Healthcare Limited said: "Our network expansion, through both organic and inorganic growth, is a strategic step towards reshaping how diagnostics is delivered in India. Kolhapur is an important healthcare hub, and the integration of Ambika Pathology Laboratory provides a formidable base to serve patients and clinicians more comprehensively. Ambika's facility will be developed into a mini regional reference lab, strengthening our specialised diagnostics capabilities in the region. Our focus remains on seamless integration, operational excellence, and digital innovation to build connected regional clusters that deliver world-class diagnostics and enable faster, more accurate insights for better patient outcomes."

Dr. Rajendra Patil, Founder and Chief of Lab, Ambika Pathology, Laboratory, said: "Partnering with Metropolis marks a significant milestone, as it brings global standards of science, technology, and



operational excellence to our region. This collaboration will not only widen the scope of specialised tests available in Kolhapur but also create new opportunities for medical professionals and patients to benefit from advanced diagnostic innovations. We are confident that Ambika’s local legacy, combined with Metropolis’ scale and expertise, will set new benchmarks in diagnostic services for Western Maharashtra.”

About Metropolis Healthcare Limited: Established in 1981, Metropolis Healthcare Limited is India’s second-largest diagnostic chain, led by visionary leader Ms. Ameera Shah, Promoter and Executive Chairperson. With over four decades of excellence, Metropolis has been a pioneer in delivering best-in-class diagnostic services to patients, healthcare providers, and corporates across India and Africa. The company’s extensive footprint spans 28 states, 7 Union Territories, and over 750 towns in India, supported by a robust network of more than 220 laboratories, 4,450+ service centers, and over 10,000 touchpoints.

Each year, Metropolis serves millions of individuals by providing actionable health insights that empower better clinical outcomes. Metropolis offers a comprehensive range of more than 4,000 tests and profiles, including advanced tests for diagnosing cancer, neurological disorders, infectious diseases, and various genetic abnormalities. The company’s commitment to quality and accuracy is reinforced by its consistent CAP proficiency score of over 98% for the past decade, placing it among the top 1% of laboratories worldwide for quality assurance. The Metropolis philosophy is built on the pillars of technological superiority, a warm, patient-centric approach, and reliable diagnostic reports. For more information, please visit www.metropolisindia.com or click on [Twitter](#), [Facebook](#), or [LinkedIn](#)

For further details please contact:

Metropolis Healthcare Ltd	Avian WE
Head - Corporate Communications: Jeyasingh Balakrishnan- +91 9833836185 jeyasingh.b@metropolisindia.com	Aniket Singh Saran: +91 9560476715 aniket@avianwe.com